Krystal Biotech ( NASDAQ:KRYS ) is trading 2.7% higher on analyst update

Krystal Biotech, Inc. Share Price (NASDAQ:KRYS – Get Free Report ) was up 2.7% during trading on Wednesday after HC Wainwright upped their target price for the stock from $200.00 to $221.00. HC Wainwright currently has a buy rating on the stock. Krystal Biotech traded as high as $203.60 and last traded at $203.57. During trading, 76,820 shares were traded, down 79% from the session’s average volume of 361,466 shares. Shares previously closed at $198.22.

A number of other research firms have recently issued reports on KRYS. Citigroup restated a “neutral” rating and set a $204.00 target price (up from $195.00) on shares of Krystal Biotech in a report on Tuesday, August 6th. Evercore ISI upped their target price on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research report on Monday, August 12th. Finally, Chardan Capital boosted their target price on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a report on Monday, August 5th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Krystal Biotech presently has a consensus rating of “Moderate Buy” and an average target price of $190.22, based on data from MarketBeat.com.

Check out our latest analysis of KRYS

Insider buying and selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the completion of the sale, the insider now owns 1,525,882 shares in the company, valued at approximately $268,189,020.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC’s website. 14.10% of the shares are owned by company insiders.

Institutional inputs and outputs

A number of hedge funds have recently made changes to their positions in the business. Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Krystal Biotech in the second quarter valued at about $555,000. Creative Planning raised its holdings in Krystal Biotech by 21.6% in the 2nd quarter. Creative Planning now owns 3,484 shares of the company’s stock worth $640,000 after buying an additional 618 shares in the last quarter. Algert Global LLC acquired a new stake in shares of Krystal Biotech in the second quarter valued at approximately $340,000. Driehaus Capital Management LLC boosted its stake in Krystal Biotech by 7.8% in the second quarter. Driehaus Capital Management LLC now owns 118,746 shares of the company’s stock worth $21,807,000 after buying an additional 8,547 shares in the last quarter. Finally, Deerfield Management Company LP Series C bought a new position in shares of Krystal Biotech in the second quarter valued at about $295,000. 86.29% of the shares are currently owned by institutional investors and hedge funds.

Krystal Biotech stock down 4.3%

The company has a 50-day moving average of $193.63 and a 200-day moving average of $172.84. The company has a market cap of $5.58 billion, a PE ratio of 104.40 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS – Get Your Free Report ) last issued its quarterly earnings data on Monday, August 5th. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.03. The company had revenue of $70.28 million for the quarter, compared to the consensus estimate of $65.27 million. In the same quarter last year, the company posted earnings per share of ($1.25). Krystal Biotech’s revenue increased by 70283900.0% year-over-year. As a group, equities analysts predict that Krystal Biotech, Inc. will display 2 BPA for the current year.

About Krystal Biotech

(Get a free report)

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops and commercializes genetic medicines for patients with rare diseases in the United States. It markets VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

See Also

Get news and reviews for Krystal Biotech Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Krystal Biotech and related companies with MarketBeat.com’s FREE daily email newsletter.